EYC-0305 - (OVERTURE)

Aug. 18, 2026: Eyconis announced first patients were dosed in OVERTURE, a first-in-human, open-label Phase 1b/2a trial of EYC-0305 in treatment-naïve patients with neovascular (wet) age-related macular degeneration, marking the company’s transition to a clinical-stage biotech.

EYC-0305 is an investigational long-acting anti-VEGF antibody fragment using TransCon technology licensed from Ascendis Pharma (NASDAQ: ASND). The study is evaluating multiple ascending intravitreal dose levels, with patients expected to receive a single dose every 24 weeks and no traditional monthly loading doses. Primary focus is safety and tolerability; additional measures include pharmacokinetics, immunogenicity, disease activity, and vision.

The company said EYC-0305 is being developed to provide sustained retinal drug exposure for six months or longer after a standard intravitreal injection, with potential durability beyond six months to be assessed for future development. ClinicalTrials.gov identifier: NCT07587515.

Eyconis also said EYC-0305 is being developed for wet AMD with potential applicability in other retinal diseases including diabetic macular edema, diabetic retinopathy, and retinal vein occlusion.